Abstract: A method of a first terminal may include: identifying first RB set(s) to be used for SL communication among consecutive RB sets through an LBT procedure; identifying a first subchannel group included in the first RB set(s) and a second subchannel group including a first PRB in the first RB set(s), the first PRB being not included in the first subchannel group; configuring the first PRB within the second subchannel group as an SL communication resource; and transmitting, to a second terminal, control information indicating that the first PRB is configured as the SL communication resource.

Abstract: The present invention relates to a composition for improving memory, or a composition for preventing and treating Alzheimer's disease, or a method for preparing said compositions, or a treatment method, wherein said compositions are characterized by comprising a cooked silkworm product and an Angelica root extract as effective components. As the present invention provides compositions using an Angelica root extract and a silkworm product rich in silk proteins and functional materials derived from mulberry leaves to improve memory and prevent or treat Alzheimer's disease, various health supplement products or drugs using the present invention are expected to be developed and commercialized, making it possible to fundamentally prevent and treat aging and dementia associated with aging, which are arising as a major problem in modern societies, and also to provide benefits of memory improvements in various other demographics, such as students, students studying for exams, office workers, etc.

Abstract: The present invention relates to a pharmaceutical composition for the regeneration of nerves comprising Vax protein as an active ingredient. Vax1 is secreted in the ventral hypothalamus (vHT) explant separated from a mouse. The secreted Vax1 combines with extracellular sugar group of heparan sulfate proteoglycans (HSPGs) existing in retinal ganglion cell (RGC) axon of the retinal explant co-cultured so as for the complex invades into axonplasm. Then, the Vax1 conjugated with the sugar group activates the local protein synthesis to accelerate the growth of retinal ganglion cell axon. In some embodiments, Vax protein or a nucleic acid encoding the protein, can be used in a pharmaceutical composition for the regeneration of nerves.

Abstract: The present invention relates to a pharmaceutical composition for the regeneration of nerves comprising Vax protein as an active ingredient. Vax1 is secreted in the ventral hypothalamus (vHT) explant separated from a mouse. The secreted Vax1 combines with extracellular sugar group of heparan sulfate proteoglycans (HSPGs) existing in retinal ganglion cell (RGC) axon of the retinal explant co-cultured so as for the complex invades into axonplasm. Then, the Vax1 conjugated with the sugar group activates the local protein synthesis to accelerate the growth of retinal ganglion cell axon. In some embodiments, Vax protein or a nucleic acid encoding the protein, can be used in a pharmaceutical composition for the regeneration of nerves.

Abstract: The present invention relates to a mobile communication system, particularly relates to a power estimating apparatus of CDMA(code division multiple access) system which performs a power control of a down link or an up link in the CDMA mobile communication system and performs a power control about a CDMA signal by using an extended walsh code. A power estimating method in a CDMA system for distinguishing CDMA channels with a walsh code which is orthogonal to all CDMA channels, comprising the steps of making an extended walsh code having a new format, which is orthogonal to all CDMA channels, by extending a length(code stream) of the walsh code which is used for distinguishing the CDMA channels, according to a walsh function, and estimating a receiving power by correlating a receiving signal with the extended walsh code.